1800 244 735

Helpline (02) 9874 9777

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam.

An existing drug…for huntingtin lowering?

The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to branaplam for treatment of Huntington’s disease.

Branaplam was originally developed for the treatment of the neurological disorder spinal muscular atrophy (SMA) and is still under clinical investigation for this purpose. Branaplam works by interfering with how genetic messages are processed in cells and can increase the levels of a protein called SMN2. Boosting levels of SMN2 helps SMA patients who have lower levels of this protein which is the underlying cause of the disease in many cases.

Interestingly, it seems that branaplam also reduces the levels of the huntingtin gene message and the huntingtin protein. This is what huntingtin-lowering therapies all aim to do and is how many researchers and companies hope to treat Huntington’s disease.

The huntingtin-lowering therapies currently in clinical trials need to be given through spinal injections or brain surgery. Unlike these, branaplam is a small molecule drug, which means it can be taken as a tablet. If Novartis can show that branaplam is an effective treatment for HD, this would mean that it could be given as a pill, a more convenient option for HD patients!

Orphan Drug Designation – and what’s next

The FDA’s decision to grant orphan drug status is usually done when a medicine is being developed for the treatment of a rare disease like Huntington’s disease. Granting orphan drug status can provide benefits and incentives to the company who has developed the drug, in this case Novartis, to encourage the development of new medicines for diseases with only a small population of patients.

There is still a lot that scientists don’t understand about using branaplam to treat HD patients. Pill-based treatments are expected to work on the whole body, not just the brain and it is not very clear what the effects of lowering huntingtin everywhere might be. Additionally, we already know that branaplam can alter the levels of both SMN2 and huntingtin so it is probably the case that levels of other proteins might also change with branaplam treatment. Without a complete and precise understanding of what scientists call the “mechanism of action” of a drug, this could make it complicated to work out exactly how branaplam treatment might alter HD symptoms. The good news is that the drug has already been shown to be safe in small groups of SMA patients.

Novartis is now designing a Phase II clinical trial for patients with HD, which is planned for launch in 2021. We hope to bring you more updates soon!

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more